Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan, henagliflozin, and their combination in IgA nephropathy
ChiCTR2400080435Phase 3Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ambrisentan and henagliflozin in IgA nephropathy (IgAN) (6 arms), sponsored by Peking University First Hospital. Primary endpoint: Urinary protein-to-creatinine ratio. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
ambrisentanhenagliflozin
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2400080435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080435.